Will This Drug Stock Explode After Earnings As It Did Last Quarter?

Group 1 - ANI Pharmaceuticals is currently pausing in a flat base after retaking a closely watched moving average [1] - The company topped second-quarter earnings estimates by 28% according to IBD Stock Checkup [1] - ANI Pharmaceuticals is recognized as a leader in developing treatments for rare diseases [1] Group 2 - The stock has shown rising relative price performance but is still shy of key benchmarks [4] - ANI Pharmaceuticals has achieved a relative strength rating upgrade, hitting an 80-plus RS rating [4] - The stock is included in the IBD 50 Growth Stocks To Watch list [1]